Top Markets
#1 Helium Helium +47.22%
#2 Pons Pons +39.28%
#3 TENDIES TENDIES +24.70%
#4 pipedog pipedog +23.35%
#5 Seeker Seeker +21.59%
#6 UnifAI Network UnifAI Network +19.84%
#7 Bounce Bounce +17.09%
#8 Songbird Songbird +11.97%
#9 Wrapped STX (Velar) Wrapped STX (Velar) +10.49%
#10 OSK OSK +10.30%
Coin of the day
Helium Helium
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
Rang in aandelen #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
Aandeelprijs
$9.50
Laatst gesynchroniseerd: 2025-01-08
Marktkapitalisatie
$819.52M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Poseida Therapeutics, Inc. (PSTX)

Categorie

Healthcare
P/S-ratio voor Poseida Therapeutics, Inc. (PSTX)
P/S-ratio op August 2026 TTM: 14.31
Volgens de meest recente financiële rapporten en aandelenkoers van Poseida Therapeutics, Inc. is de huidige P/S-ratio (TTM) 14.31. Eind 2022 had het bedrijf een P/S-ratio van 2.92.
P/S-ratiohistoriek voor Poseida Therapeutics, Inc. van 2016 tot 2026
P/S-ratio aan het einde van elk jaar
Jaar P/S-ratio Wijzigen
2026 (TTM) 14.31 205.78%
2023 4.68 60.18%
2022 2.92 -99.98%
2021 13.55K 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 -100.00%
2017 204.33 119.21%
2016 93.21 0.00%
P/S-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/S-ratio Verschil in P/S-ratio Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -28.95%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -29.22%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -79.37%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -21.20%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH